Millennium Management
ADMA icon

Millennium Management’s ADMA Biologics ADMA Stock Holding History

Millennium Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$1.98M – 5814
2025
Q1 		$1.98M Sell
100,000
-50,000
-33% -$865K ﹤0.01% 3793
2024
Q4 		$2.57M Buy
+150,000
New +$2.82M ﹤0.01% 3426

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management's ADMA Position: Q1 2026 in Review

Millennium Management increased its ADMA Biologics (ADMA) stake by 413% in Q1 2026, buying an estimated $43.6M and bringing the position to 3,434,449 shares worth $30.9M. The position accounts for 0.01% of the portfolio, ranked #1204.

Millennium Management first reported a position in ADMA in Q3 2017 and has held it in 31 quarters since. The position peaked at $42.6M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Millennium Management held 3,434,449 shares of ADMA Biologics worth $30.9M as of Q1 2026.
  • Millennium Management bought 2,764,778 ADMA Biologics shares in Q1 2026, an estimated $43.6M.
  • ADMA Biologics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1204 holding.
  • Millennium Management first reported a position in ADMA Biologics in Q3 2017 and has held it in 31 quarters since.
  • Millennium Management's ADMA Biologics position peaked at $42.6M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.